In the phase 3 BOSTON trial, a team of researchers led by Meletios Dimopoulos, MD, found that selinexor/bortezomib/dexamethasone (SVd) significantly improved survival compared with bortezomib/dexamethasone (Vd) alone in patients with multiple myeloma who had received one to three prior lines of therapy. The trial's results were recently presented in the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. In this interview with i3 Health, Dr. Dimopoulos, Chairman of the Department of Clinical Therapeutics at National and Kapodistrian University of Athens School of Medicine, discusses the benefits that SVd has to offer for patients with relapsed/refractory multiple myeloma.
What are some of the most challenging aspects of treating patients with relapsed/refractory multiple myeloma?
Meletios Dimopoulos, MD: Despite significant improvements in the outcomes of patients with multiple myeloma, most patients will relapse and become resistant to all available therapies. Thus, there is a continuous struggle to find novel treatment approaches for these patients.
Can you comment on the significance of your findings?
Dr. Dimopoulos: The combination of oral selinexor with weekly bortezomib and dexamethasone showed significant activity in patients with relapsed/refractory multiple myeloma who had received one to three prior lines of therapy. This combination may provide an additional treatment option for patients with this disease. There is a particular interest for patients who have developed resistance to lenalidomide.
What additional treatment advances are on the horizon for these patients?
Dr. Dimopoulos: Novel immunotherapies, including antibody-drug conjugates such as T-cell engager therapies and chimeric antigen receptor (CAR) T cells, are currently being actively investigated.
Do you have any words of advice for community oncologists treating patients with relapsed/refractory multiple myeloma?
Dr. Dimopoulos: Because of continuous improvements in the treatment of these patients, practicing oncologists should closely follow the most recent literature in order to provide state-of-the-art treatment to their patients.
About Dr. Dimopoulos
Meletios Dimopoulos, MD, is a Professor of Hematology/Medical Oncology and Chairman of the Department of Clinical Therapeutics at National and Kapodistrian University of Athens School of Medicine in Athens, Greece. He is also Chairman of the Greek Myeloma Study Group and the Balkan Myeloma Study Group. Dr. Dimopoulos specializes in the treatment of hematologic malignancies, with particular expertise in multiple myeloma and other plasma cell dyscrasias. He serves on the scientific advisory boards of the International Myeloma Foundation, the International Waldenstrom's Macroglobulinemia Foundation, and the Multiple Myeloma Research Foundation. He is also Associate Editor of Current Hematologic Malignancy Reports and is an editorial board member or reviewer of several other journals, including the New England Journal of Medicine, the Journal of Clinical Oncology, Blood, and Leukemia and Lymphoma. Dr. Dimopoulos has authored over 1,000 publications in peer-reviewed journals.
For More InformationDimopoulos MA, Delimpasi S, Simonova M, et al (2020). Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: initial results of the phase III BOSTON study. J Clin Oncol (ASCO Virtual Scientific Program), 38(suppl_15). Abstract 8501. DOI:10.1200/JCO.2020.38.15_suppl.8501